SUBSCRIBE
3 minutes
Motherwell-based biotech ICL Therapeutics has set its sights on a Series A round and an IPO following its most recent investment round, and is on track to commercialise a suite of anti-viral medicines for the treatment of respiratory infections including SARS-CoV-2. ILC’s lead hybrid interfero
